Prophylaxis in hemophilia
Clin. biomed. res
; 43(1): 58-68, 2023.
Article
en En
| LILACS
| ID: biblio-1435960
Biblioteca responsable:
BR18.1
ABSTRACT
Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) or factor IX (Hemophilia B). Prophylaxis the regular administration of therapeutic products to maintain hemostasis and prevent bleeding is the mainstream of treatment. Addressing the development and scientific evidence for administrating prophylaxis is the goal of this review. Prophylaxis is the therapeutic modality of choice for people with severe hemophilia, being considered, in principle, a lifelong treatment. It should have an early onset, ideally as a primary, or at least secondary. Even lifelong tertiary prophylaxis seems to offer benefit, although further studies are still lacking. Individualized strategies should lead to an optimization of the dilemma between better joint outcomes versus involved costs.
Asunto(s)
Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
Factor VIII
/
Hemofilia B
/
Hemofilia A
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin. biomed. res
Asunto de la revista:
MEDICINA
Año:
2023
Tipo del documento:
Article